In the era of precision medicine, the application of molecular spectrum analysis in CLCNEC should be expanded, whether it is distinguishing between SCLC like and Nsclc like CLCNEC through TP53 and RB1 co mutations, or searching for oncogene aberrations to perform corresponding molecular targeted therapies. The gene discussed is TP53; the disease is small cell lung carcinoma.